B+
Bull case
20%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
PCRX
Pacira BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The commercial EXPAREL franchise may continue gaining share, while PCRX-201 manufacturing readiness, ASCENT progress, and the Zimmer Biomet partnership provide potential longer-term optionality.
Posture
Constructive
Lead driver
Value
What changed
News driver: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies.
What can break
Commercial upside depends on sustained access expansion and outpatient uptake.
Momentum
99
Value
65
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $30.00 · Bear $18.00Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $34.79
Why
Momentum99 · Δ7d +0.8
Value65 · Δ7d -0.2
Sentiment47 · Δ7d -0.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • News driver: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies.
- • Value remains the lead driver in the composite, 7D delta -0.2.
Contradictions & invalidation
- • Commercial upside depends on sustained access expansion and outpatient uptake.
- • Macroeconomic softness in elective procedures could pressure EXPAREL demand.
- • Elective-procedure softness, execution risk around PCRX-201 development, and limited evidence of analyst estimate or target revisions constrain conviction.
Catalyst clock
2026-08-04
Q2 2026 earnings follow-up
Lead driver: Value · See fundamentals
Momentum
99
8% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+35.2
Value
65
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-2.7
Sentiment
47
45% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-39.6
Why this grade
Composite grade B. Momentum 99.3 / Value 65.1 / Sentiment 46.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$1.45B
Beta
0.25
Shares Out
39.86M
P/E (TTM)
53.8
P/S (TTM)
1.51
P/FCF (TTM)
8.69
Rev YoY
+6.2%
EPS YoY
-208.3%
Gross Margin
+71.5%
Op Margin
+3.7%
Net Debt
$179.78M
Current Ratio
5.04
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data